Acurx Pharmaceuticals, Inc. Regains Full Compliance with Nasdaq Minimum Closing Bid Price and Stockholder Equity Rules

Rhea-AI Summary

Acurx Pharmaceuticals (NASDAQ:ACXP), a late-stage biopharmaceutical company focused on developing novel antibiotics, has successfully regained compliance with Nasdaq's listing requirements. The company has met two critical criteria: maintaining a minimum bid price of $1.00 per share and achieving the minimum stockholders' equity threshold of $2.5 million.

This development ensures ACXP's continued listing and trading on the Nasdaq Stock Market, marking a significant milestone for the company's market presence and accessibility to investors.

Positive

• Regained full compliance with Nasdaq listing requirements
• Maintained minimum $1.00 bid price requirement
• Met minimum stockholders' equity threshold of $2.5 million
• Secured continued listing on Nasdaq Stock Market

Negative

• Previous non-compliance with Nasdaq listing requirements indicates recent financial challenges

Acurx Maintains Listing on the Nasdaq

STATEN ISLAND, N.Y., Sept. 3, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that it had received notification letters from The Nasdaq Stock Market LLC confirming that the Company has regained compliance with the minimum $1.00 bid price under Nasdaq Listing Rule 5550(a)(2), and the minimum stockholders' equity threshold of $2.5 million under Listing Rule 5550(b)(1).

The Company is now in full compliance with all Nasdaq continued listing requirements and the Company's common stock will remain listed and traded on the Nasdaq Stock Market.

About Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The Company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram+ specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin- resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug- resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Acurx's lead product candidate, ibezapolstat, for the treatment of C. difficile Infection is Phase 3 ready with plans in progress to begin international clinical trials next year subject to obtaining appropriate financing. The Company's preclinical pipeline includes development of an oral product candidate for treatment of ABSSSI (Acute Bacterial Skin and Skin Structure Infections), upon which a development program for treatment of inhaled anthrax is being planned in parallel.

To learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com.

Forward Looking Statements

Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether ibezapolstat will benefit from the QIDP designation; whether ibezapolstat will advance through the clinical trial process on a timely basis; whether the results of the clinical trials of ibezapolstat will warrant the submission of applications for marketing approval, and if so, whether ibezapolstat will receive approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies where approval is sought; whether, if ibezapolstat obtains approval, it will be successfully distributed and marketed; and other risks and uncertainties described in the Company's annual report filed with the Securities and Exchange Commission on Form 10-K for the year ended December 31, 2024, and in the Company's subsequent filings with the Securities and Exchange Commission. Such forward- looking statements speak only as of the date of this press release, and Acurx disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law.

Investor Contact:

Acurx Pharmaceuticals, Inc.
David P. Luci, President & Chief Executive Officer
Tel: 917-533-1469
Email: davidluci@acurxpharma.com

View original content:https://www.prnewswire.com/news-releases/acurx-pharmaceuticals-inc-regains-full-compliance-with-nasdaq-minimum-closing-bid-price-and-stockholder-equity-rules-302544812.html

SOURCE Acurx Pharmaceuticals, Inc.

FAQ

What Nasdaq compliance requirements did Acurx Pharmaceuticals (ACXP) meet in September 2025?

Acurx Pharmaceuticals met two key Nasdaq requirements: maintaining a minimum $1.00 bid price and achieving a minimum stockholders' equity threshold of $2.5 million.

Will Acurx Pharmaceuticals (ACXP) continue trading on Nasdaq?

Yes, ACXP will continue trading on Nasdaq as it has regained full compliance with all continued listing requirements.

What is Acurx Pharmaceuticals' (ACXP) main business focus?

Acurx is a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections.

What are the implications of Acurx (ACXP) regaining Nasdaq compliance?

Regaining compliance ensures ACXP's continued presence on Nasdaq, providing better market visibility, liquidity, and access to investors.